Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Jess Inskip, Director of Investor Research at StockBrokers.com, breaks down Q2, the AI trade, Fed policy, earnings, and where investors should look next.
Quantum computing is moving from science fiction to national strategy. Infleqtion CEO Matt Kinsella explains Trump's new executive order and what it means.
Americans traveled in record numbers over July 4th despite rising costs. Skift's Sarah Kopit explains what it says about consumers, airfares, and summer travel.
The U.S. economy is being held up in part by the AI boom, but that boom could still lead to broader prosperity or inequality, says a Nobel Prize winner.
Foundation Robotics co-founder Michael LeBlanc explains how humanoid robots are moving from the lab to military and industrial missions and what comes next.
Jeff Burnstein, President of the Association for Advancing Automation (A3), discusses humanoid robots, AI, smart manufacturing, and the future of U.S. industry.
Should kids be banned from social media? Nick Lichtenberg of Fortune breaks down the global push to restrict under-16 users and what it means for Big Tech.
